SkylineDx and leading institutes to present three abstracts on multiple myeloma risk stratification at the 56th ASH annual meeting.
Boston (U.S.) - Rotterdam (NL), November 12, 2014.
SkylineDx and leading institutes in the field of Multiple Myeloma (MM) announced today that they will present three abstracts at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH), December 6 - 9 in San Francisco, CA, U.S.A. “We are pleased that these presentations once again show the importance of the MMprofiler assay including the SKY92 expression signature in the stratification of patients with Multiple Myeloma. These presentations continue to build support for the MMprofiler as a comprehensive and valuable test for MM subtyping by Gene Expression Profiling (GEP)”, says Dharminder Chahal, CEO of SkylineDx.
SkylineDx will participate with several collaborators in the 56th ASH Annual Meeting and Exposition. The American Society of Hematology has accepted the following poster abstract presentations for their 2014 meeting.
Title: Single Sample Application of the EMC92/SKY92 Signature Using the MMprofiler (Abstract 2026)
Authors: MH Van Vliet, R Kuiper, B Dumee, L de Best, PJ van der Spek, EMEH Lesaffre, M van Duin, A Waage, S Zweegman, P Sonneveld, and EH van Beers
Date: Saturday, December 6, 2014
Presentation Time: 5:30 PM - 7:30 PM
Session Name: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Location: Moscone Center, West Building, Level 1
Summary: This abstract supports the use of the MMprofiler and EMC92/SKY92 signature on individual patients by showing data from 77 patients from 2 trials. A comparison of single sample normalization vs batch normalization showed near equivalence of EMC92/SKY92 scores, so long as standardized methods were used to generate the Affymetrix GeneChip data.
Title: Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) (Abstract 2141) Authors: MH van Vliet, J Jasielec, D Dytfeld, R Vij, B Dumee, L Bosman, L de Best, M Alonge, S Rosebeck, M Kandarpa, K McDonnell, K Griffith, EH van Beers, A Jakubowiak
Date: Saturday, December 6, 2014
Presentation Time: 5:30 PM - 7:30 PM
Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Location: Moscone Center, West Building, Level 1
Summary: This abstract shows that absence of H-MM (virtual gain[9q]) identified patients more likely to achieve =nCR by the end of 4 cycles of KRd. Additionally, the SKY92 high-risk and virtual gain(1q) signatures identify MM patients with inferior PFS in a Carfilzomib, Lenalidomide, and Dexamethasone (KRd) treatment setting. Despite the inferior outcome, these classical high-risk patients appeared to have benefited from KRd when compared to historical data of treatment without PIs, suggesting that the PI predictor signature (Van Vliet et al, EHA 2014) may also apply to carfilzomib-based treatment.
Title: Unbiased Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System (Abstract 3358)
Authors: R Kuiper, MH Van Vliet, E Van Beers, A Broyl, G Mulligan, H Avet-Loiseau, WM Gregory, G Morgan, H Goldschmidt, HM Lokhorst, M van Duin, P Sonneveld
Date: Sunday, December 7, 2014
Presentation Time: 6:00 PM - 8:00 PM
Session Name: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Location: Moscone Center, West Building, Level 1
Summary: This abstract demonstrates that GEP markers result in better prognosis predictions in unbiased comparisons than FISH markers. Prognostic markers can be improved by combining markers. The EMC92-ISS model being the best combination, offers a robust 4-group risk stratification based on biology and clinical parameters.
SkylineDx: Effective and Comprehensive Gene Testing
SkylineDx develops and markets novel research tools and diagnostic tests using gene signatures for personalized medicine in oncology. In addition, the company continues to work with academic and industrial partners on the development and commercialization of innovative markers and tests, including companion diagnostics.
You are invited to visit our booth #2627 at ASH, or we would be happy to make an appointment for a meeting at a time and location at your convenience by email: info@skylinedx.com.
For further information, questions and interviews please contact:
SkylineDx – U.S.A.
101 Federal Street
Suite 1900
Boston MA 02110
USA
Phone: +1 617 342 7098
SkylineDx B.V. – Europe
Rotterdam Science Tower
Marconistraat 16, 18th floor
3029 AK Rotterdam
The Netherlands
Phone: +31 (0)10 7038410
Help employers find you! Check out all the jobs and post your resume.
Boston (U.S.) - Rotterdam (NL), November 12, 2014.
SkylineDx and leading institutes in the field of Multiple Myeloma (MM) announced today that they will present three abstracts at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH), December 6 - 9 in San Francisco, CA, U.S.A. “We are pleased that these presentations once again show the importance of the MMprofiler assay including the SKY92 expression signature in the stratification of patients with Multiple Myeloma. These presentations continue to build support for the MMprofiler as a comprehensive and valuable test for MM subtyping by Gene Expression Profiling (GEP)”, says Dharminder Chahal, CEO of SkylineDx.
SkylineDx will participate with several collaborators in the 56th ASH Annual Meeting and Exposition. The American Society of Hematology has accepted the following poster abstract presentations for their 2014 meeting.
Title: Single Sample Application of the EMC92/SKY92 Signature Using the MMprofiler (Abstract 2026)
Authors: MH Van Vliet, R Kuiper, B Dumee, L de Best, PJ van der Spek, EMEH Lesaffre, M van Duin, A Waage, S Zweegman, P Sonneveld, and EH van Beers
Date: Saturday, December 6, 2014
Presentation Time: 5:30 PM - 7:30 PM
Session Name: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Location: Moscone Center, West Building, Level 1
Summary: This abstract supports the use of the MMprofiler and EMC92/SKY92 signature on individual patients by showing data from 77 patients from 2 trials. A comparison of single sample normalization vs batch normalization showed near equivalence of EMC92/SKY92 scores, so long as standardized methods were used to generate the Affymetrix GeneChip data.
Title: Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) (Abstract 2141) Authors: MH van Vliet, J Jasielec, D Dytfeld, R Vij, B Dumee, L Bosman, L de Best, M Alonge, S Rosebeck, M Kandarpa, K McDonnell, K Griffith, EH van Beers, A Jakubowiak
Date: Saturday, December 6, 2014
Presentation Time: 5:30 PM - 7:30 PM
Session Name: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Location: Moscone Center, West Building, Level 1
Summary: This abstract shows that absence of H-MM (virtual gain[9q]) identified patients more likely to achieve =nCR by the end of 4 cycles of KRd. Additionally, the SKY92 high-risk and virtual gain(1q) signatures identify MM patients with inferior PFS in a Carfilzomib, Lenalidomide, and Dexamethasone (KRd) treatment setting. Despite the inferior outcome, these classical high-risk patients appeared to have benefited from KRd when compared to historical data of treatment without PIs, suggesting that the PI predictor signature (Van Vliet et al, EHA 2014) may also apply to carfilzomib-based treatment.
Title: Unbiased Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System (Abstract 3358)
Authors: R Kuiper, MH Van Vliet, E Van Beers, A Broyl, G Mulligan, H Avet-Loiseau, WM Gregory, G Morgan, H Goldschmidt, HM Lokhorst, M van Duin, P Sonneveld
Date: Sunday, December 7, 2014
Presentation Time: 6:00 PM - 8:00 PM
Session Name: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Location: Moscone Center, West Building, Level 1
Summary: This abstract demonstrates that GEP markers result in better prognosis predictions in unbiased comparisons than FISH markers. Prognostic markers can be improved by combining markers. The EMC92-ISS model being the best combination, offers a robust 4-group risk stratification based on biology and clinical parameters.
SkylineDx: Effective and Comprehensive Gene Testing
SkylineDx develops and markets novel research tools and diagnostic tests using gene signatures for personalized medicine in oncology. In addition, the company continues to work with academic and industrial partners on the development and commercialization of innovative markers and tests, including companion diagnostics.
You are invited to visit our booth #2627 at ASH, or we would be happy to make an appointment for a meeting at a time and location at your convenience by email: info@skylinedx.com.
For further information, questions and interviews please contact:
SkylineDx – U.S.A.
101 Federal Street
Suite 1900
Boston MA 02110
USA
Phone: +1 617 342 7098
SkylineDx B.V. – Europe
Rotterdam Science Tower
Marconistraat 16, 18th floor
3029 AK Rotterdam
The Netherlands
Phone: +31 (0)10 7038410
Help employers find you! Check out all the jobs and post your resume.
